Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)
NCT ID: NCT05072015
Last Updated: 2022-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
150 participants
OBSERVATIONAL
2022-02-28
2028-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secundary purposes:
* Motor complications evolution at 6 months, 2 and 3 years
* MDS UPDRS III score at 6 months, 1, 2 and 3 years
* non motor complications evolution at 6 months, 1, 2 and 3 years
* cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years
* cutaneous and digestive complications at 6 months, 1, 2 and 3 years
* neuropathy occurrence at 6 months, 1, 2 and 3 years
* medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Deep Brain Stimulation and Parkinson's Disease
NCT02795663
Parkinsonian Patients Treated With Apomorphine Pump: Observatory of Skin Lesions
NCT05331573
A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study
NCT01747655
Prospective Study to Compare Results of STN-DBS Between Early Treated and Late-treated PD Patient
NCT01274832
Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease
NCT00354133
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with fluctuations and/or dyskinesia , who need treatment with deep brain stimulation, apomorphin pump or duodopa pump
* MOCA \>20
* patient \>21 years of age
* patient who has signed protocol acceptation
Exclusion Criteria
* patient with another parkinsonian syndrome than Parkinson' s disease
* MOCA\<20
* Patient who does not need second line treatment
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mathieu ANHEIM
Role: PRINCIPAL_INVESTIGATOR
Les Hôpitaux Universitaires de Strasbourg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mathieu ANHEIM
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8355
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.